• Hanna M Crow, Leland Graves, and Abeer Anabtawi.
• University of Kansas Medical Center - Department of Endocrinology, Diabetes and Clinical Pharmacology, Kansas City, KS, USA. Electronic address: hcrow@kumc.edu.
• Am. J. Med. Sci. 2022 Oct 1; 364 (4): 461465461-465.

AbstractBone disease is a known complication of cystic fibrosis (CF). To date, there have been no reports on the effectiveness of romosozumab, monoclonal antibody to sclerostin, to treat CF-related bone disease. We report a case of a 46-year-old premenopausal female with CF-related bone disease and multiple fractures who was treated with romosozumab. After one year of therapy with romosozumab, the patient tolerated therapy and bone mineral density (BMD) significantly improved. Of the currently available anti-resorptive or anabolic osteoporosis medications, only bisphosphonates have been studied in individuals with CF. This report highlights that romosozumab may be an effective alternative treatment modality in selected patients with CF at high risk for fractures. Further studies are warranted to evaluate the efficacy and safety profile of romosozumab in people with CF.Copyright © 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

25 keywords...

hide…